|
GTF2A1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.94910000548421E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.6728999999468E-06 |
| Normal-vs-Stage2 |
7.032000E-04 |
| Normal-vs-Stage3 |
1.7089999970743E-08 |
| Normal-vs-Stage4 |
4.78849999996367E-06 |
| Stage1-vs-Stage2 |
9.379800E-01 |
| Stage1-vs-Stage3 |
6.524000E-02 |
| Stage1-vs-Stage4 |
2.680800E-01 |
| Stage2-vs-Stage3 |
1.846590E-01 |
| Stage2-vs-Stage4 |
3.308200E-01 |
| Stage3-vs-Stage4 |
8.664800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.09540000023689E-07 |
| Normal-vs-AfricanAmerican |
7.050400E-02 |
| Normal-vs-Asian |
1.64079999998012E-06 |
| Caucasian-vs-AfricanAmerican |
1.752970E-01 |
| Caucasian-vs-Asian |
3.446400E-01 |
| AfricanAmerican-vs-Asian |
9.358000E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.42099995606537E-09 |
| Normal-vs-Female |
1.86652999999426E-05 |
| Male-vs-Female |
3.247100E-04 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.048110E-04 |
| Normal-vs-Age(41-60Yrs) |
4.83690000052661E-07 |
| Normal-vs-Age(61-80Yrs) |
1.55260000411772E-08 |
| Normal-vs-Age(81-100Yrs) |
3.696500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.521200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.805500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.766200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.814200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.347000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.571000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.920000E-03 |
| Classical-VS-Follicular |
3.530000E-01 |
| Classical-VS-Other |
7.834100E-02 |
| Classical-VS-Normal |
1.63447000000039E-05 |
| Tall-VS-Follicular |
7.274200E-02 |
| Tall-VS-Other |
2.896000E-01 |
| Tall-VS-Normal |
2.58100000261052E-08 |
| Follicular-VS-Other |
1.352560E-01 |
| Follicular-VS-Normal |
1.51462999999907E-05 |
| Other-VS-Normal |
7.020400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.11839999986196E-07 |
| Normal-vs-N1 |
7.95190000000279E-05 |
| N0-vs-N1 |
6.966400E-01 |
|
|
